Expansion of the filgrastim biosimilar in Europe, the United States and Asia
First written in FY2016. 2 of 5 entries say "Restated". Latest entry: FY2020.
No other company in this theme has enough history to compare yet.
- FY2020RestatedAnnual report
「The company aims to enter the biosimilars field globally, as the global market for a single biologic can be worth several hundred billion yen and healthcare authorities in various countries are raising their requirements for generic products.」
Reaffirming the goal of entering global markets through the biosimilars business as a whole. - FY2018DroppedAnnual report
「The company aims to enter the biosimilars field globally, as the global market for a single biologic can be worth several hundred billion yen and healthcare authorities in various countries are raising their requirements for generic products.」
The current year's text contains no specific discussion of commercializing the filgrastim biosimilar in Europe, the United States or Asia, and instead frames the objective as global entry for the biosimilars business as a whole. - FY2017RestatedAnnual report
「The company will also consider overseas commercialization to enhance the value of this product.」
The overseas expansion of the filgrastim biosimilar continues to be described as being at the consideration stage. - FY2017-Q1AdvancedAnnual report
「On the same day, the company also entered into a basic agreement with Changchun Changsheng Bio-Tech Co., Ltd. concerning the commercialization of the biosimilar in the Chinese market, marking the first step in the overseas expansion of its biosimilars.」
Overseas expansion has progressed from the consideration stage to the concrete stage of entering into a basic agreement with a Chinese company for commercialization in the Chinese market. - FY2016First statedAnnual report
「The company will also consider commercialization in the European, U.S. and Asian markets to enhance the value of this product.」
The company is considering commercialization in overseas markets for products already launched in Japan.